Saturday, August 2, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Add-On Simvastatin Shows No Benefit in Depression

June 13, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE:

In a trial of patients with major depressive disorder (MDD) and obesity, adding simvastatin to escitalopram treatment led to no significant reduction in depressive symptoms compared with placebo; however, the combination effectively reduced levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP).

METHODOLOGY:

  • This confirmatory, double-blind, placebo-controlled trial included 160 adults (mean age, 39 years; 79% women) with MDD and comorbid obesity from nine tertiary care centres in Germany.
  • Participants were randomly assigned to receive either simvastatin (40 mg/d; n = 81) or placebo (n = 79) as add-on to escitalopram (10 mg for the first 2 weeks, then increased to 20 mg until the end of the study) for 12 weeks.
  • The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to week 12.
  • The key secondary outcome was the change in self-reported Beck Depression Inventory II (BDI-II) scores.

TAKEAWAY:

  • Compared with the use of add-on placebo, the use of add-on simvastatin led to no significant change in MADRS scores (P = .71) and BDI-II scores (P = .70).
  • Moreover, compared with the use of add-on placebo, the use of add-on simvastatin led to a significant reduction in levels of LDL cholesterol (P < .001), total cholesterol (P < .001), and CRP (P = .003).
  • Add-on simvastatin did not affect any mental health-related secondary endpoint, despite improving the cardiovascular risk profile.
  • Four severe adverse events were reported, with no significant differences observed between the groups.

IN PRACTICE:

“Even though simvastatin did not exert additional antidepressive effects in our study, it had the expected and well-known effects on lipids and inflammatory activity. Given that both MDD and obesity are associated with increased cardiovascular risk and higher mortality, statins should be prescribed in this comorbid group of patients following the guidelines for statin use in primary prevention,” the authors wrote.

SOURCE:

This study was led by Christian Otte, MD, Charité — Universitätsmedizin Berlin, Berlin, Germany. It was published online on June 04 in JAMA Psychiatry.

LIMITATIONS:

This study was conducted in tertiary care centres in a high-income country, with patients showing moderate symptom severity and a high response rate, which limited its generalisability. Additionally, participants with an established indication for statin treatment and those with a history of suicide attempt were not included.

DISCLOSURES:

This study was supported by a grant from the German Ministry of Education and Research and sponsored by Charité — Universitätsmedizin Berlin. Several authors reported receiving grants and personal fees from various sources, outside the submitted work. Details are provided in the original article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link : https://www.medscape.com/viewarticle/add-simvastatin-shows-no-benefit-depression-2025a1000fny?src=rss

Author :

Publish date : 2025-06-13 12:00:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

FDA Bucks Advisors to Approve Mitomycin for NMIBC

Next Post

DIF Microscopy Helps Diagnose Pediatric Skin Diseases

Related Posts

Health News

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

August 1, 2025
Health News

‘It’s Gonna Be (Ly)me’: Justin Timberlake Brings Attention, Awareness to Disease

August 1, 2025
Health News

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

August 1, 2025
Health News

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

August 1, 2025
Health News

Time Your Meals, Tune Your Metabolism

August 1, 2025
Health News

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval

August 1, 2025
Load More

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

August 1, 2025

‘It’s Gonna Be (Ly)me’: Justin Timberlake Brings Attention, Awareness to Disease

August 1, 2025

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

August 1, 2025

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

August 1, 2025

Time Your Meals, Tune Your Metabolism

August 1, 2025

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval

August 1, 2025

Bone Health in Duchenne Muscular Dystrophy

August 1, 2025

Could we get quantum spookiness even without entanglement?

August 1, 2025
Load More

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version